Methods For Inhibiting The Binding Of Endosialin To Ligands
AssigneeMorphotek, Inc.
InventorsYuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
Life of this patent
Estimating the term…
Abstract
The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
Claims73
A method for inhibiting the interaction of an endosialin-expressing cell with a ligand for endosialin, comprising contacting said endosialin-expressing cell with an antibody that specifically binds endosialin or an antigen-binding fragment thereof, wherein binding of said antibody or antigen-binding fragment to endosialin expressed on the surface of the endosialin-expressing cell inhibits the interaction of said endosialin-expressing cell with said ligand for endosialin.
A method for inhibiting neovascularization in a subject comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment that specifically binds endosialin, wherein said antibody or antigen-binding fragment inhibits the interaction of endosialin expressed on the surface of a cell with a ligand for endosialin, and wherein inhibiting said interaction of endosialin expressed on the surface of said cell with said ligand for endosialin inhibits neovascularization of a tissue, organ, or neoplasm in the subject.
A method for inhibiting angiogenesis in a subject comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment that specifically binds endosialin, wherein said antibody or antigen-binding fragment inhibits the interaction of endosialin expressed on the surface of a cell with a ligand for endosialin, and wherein inhibiting said interaction of endosialin expressed on the surface of said cell with said ligand for endosialin inhibits angiogenesis of a tissue, organ, or neoplasm in the subject.
A method for inhibiting the interaction of an endosialin-expressing cell with a ligand for endosialin, comprising contacting said ligand for endosialin with an antibody or antigen-binding fragment that specifically binds said ligand for endosialin, thereby obstructing the interaction of said ligand for endosialin with endosialin expressed on the surface of said cell, wherein said obstructing inhibits the interaction of said endosialin-expressing cell with said ligand for endosialin.
A method for inhibiting neovascularization in a subject comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment that specifically binds an endosialin ligand, thereby obstructing interaction of the endosialin ligand with endosialin, and inhibiting neovascularization of a tissue, organ, or neoplasm in the subject.
A method for inhibiting angiogenesis in a subject comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment that specifically binds an endosialin ligand, thereby obstructing interaction of the endosialin ligand with endosialin, and inhibiting angiogenesis in a tissue, organ, or neoplasm in the subject.
A method for inhibiting the interaction of an endosialin-expressing cell with a ligand for endosialin, comprising obstructing endosialin expressed on the surface of said cell, wherein said obstructing inhibits the interaction of said cell with said ligand.
A method for inhibiting the interaction of an endosialin-expressing cell with a ligand for endosialin, comprising inhibiting the expression of endosialin in an endosialin-expressing cell, wherein inhibiting the expression of endosialin in said cell inhibits the interaction of said cell with said ligand.
Dependencies are inferred from the claim text.